Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.

Clicks: 366
ID: 107767
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #8 of 37 articles by views in Transboundary and emerging diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Currently, COVID-19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course, and treatment efficacy of COVID-19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from January 20 to February 8, 2020. Clinical outcomes were followed up until March 26, 2020. The viral shedding duration, full clinical course, and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID-19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS-CoV-2. In total, the median SARS-CoV-2 shedding period and clinical course were 12 (IQR: 9-17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16-24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively; and ICU patients had longer median viral shedding periods (21 [17-24] vs 11 [9-15]) and clinical courses (30 [22-33] vs 19 [15.8-22]) than non-ICU patients (both p<0.0001). SARS-CoV-2 clearances occurred at least 2 days before fatality in 3 non-survivors. Current treatment with any antiviral agent or combination did not present the benefit of shortening viral shedding period and clinical course (all p>0.05) in real-life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current antiviral therapies were ineffective for shortening viral shedding duration and clinical course in real-world settings. These findings expand our knowledge of the SARS-CoV-2 infection and may be helpful for management of the epidemic outbreak of COVID-19 worldwide. Further studies concerning effective antiviral agents and vaccines are urgently needed.
Reference Key
zeng2020clinicaltransboundary Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zeng, Qing-Lei;Li, Guang-Ming;Ji, Fanpu;Ma, Shu-Huan;Zhang, Guo-Fan;Xu, Jiang-Hai;Lin, Wan-Bao;Xu, Guang-Hua;Zhang, Guo-Qiang;Li, Guo-Tao;Cui, Guang-Lin;Liu, Na;Zeng, Fan-Jun;Ai, Zhi-Guo;Xu, Guang-Feng;Liu, Na;Liang, Jie;Zhang, Min-Min;Li, Cheng;Zhang, Zhi-Hao;Wang, Ze-Shuai;Li, Zongfang;Yu, Zu-Jiang;
Journal Transboundary and emerging diseases
Year 2020
DOI
10.1111/tbed.13674
URL
Keywords
antiviral efficacy Epidemiology shaanxi province clinical course coronavirus disease 2019 (covid-19) henan province severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.